Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

Plus, news about TScan Ther­a­peu­tics:

His­to­gen files for Chap­ter 11 bank­rupt­cy: The biotech, which stopped work in Sep­tem­ber, filed a pe­ti­tion with the US Bank­rupt­cy Court for the South­ern Dis­trict of Cal­i­for­nia. Its next steps in­clude con­firm­ing a plan of liq­ui­da­tion to dis­trib­ute val­ue to stake­hold­ers. — Ay­isha Shar­ma 

Barinthus Bio touts Ph1b/2 HPV da­ta: The com­pa­ny’s im­munother­a­py can­di­date, VTP-200, met the pri­ma­ry safe­ty end­point in a tri­al of 108 women with high-risk HPV-as­so­ci­at­ed low-grade cer­vi­cal le­sions. The group with the high­est treat­ment dose achieved a 60% high-risk HPV clear­ance rate at 12 months ver­sus a 33% clear­ance rate for place­bo. — Ay­isha Shar­ma 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.